Market Newsdesk

ATHENS, Greece, April 11, 2025 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE:DLNG) (the “Partnership”), an owner and operator of liquefied natural gas (“LNG”) carriers, announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”).

The Annual Report is available through the Partnership’s website.

Alternatively, unitholders may also receive a hard copy of the Annual Report, including the Partnership’s annual audited financial statements, free of charge, by request to Capital Link, Inc., using the contact details provided at the end of this press release.

About
Dynagas
LNG
Partners
LP

Dynagas LNG Partners LP. (NYSE: DLNG) is a master limited partnership that owns and operates LNG carriers employed on multi-year charters. The Partnership’s current fleet consists of six LNG carriers, with an aggregate carrying capacity of approximately 914,000 cubic meters.

Visit the Partnership’s website at www.dynagaspartners.com. The Partnership’s website and its contents are not incorporated into and do not form a part of this release.

Contact
Information:

Dynagas
LNG
Partners
LP
Attention: Michael Gregos
Tel. +30 210 8917960
Email: [email protected]

Investor
Relations /
Financial
Media:

Nicolas Bornozis
Markella Kara
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, NY 10169
Tel. (212) 661-7566
E-mail: [email protected]

Forward-Looking
Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Partnership desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “will,” “may,” “should,” “expect,” “expected,” “pending” and similar expressions identify forward-looking statements. These forward-looking statements are not intended to give any assurance as to the future results and should not be relied upon.

The forward-looking statements in this press release are based upon various assumptions and estimates, many of which are based, in turn, upon further assumptions, including without limitation, examination by the Partnership’s management of historical operating trends, data contained in its records and other data available from third parties. Although the Partnership believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Partnership’s control, the Partnership cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Partnership’s view, could cause actual results to differ materially from those discussed, expressed or implied, in the forward-looking statements include, but are not limited to, the strength of world economies and currency fluctuations, general market conditions, including fluctuations in charter rates, ownership days, and vessel values, changes in supply of and demand for LNG shipping capacity, changes in the Partnership’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Partnership’s vessels, availability of financing and refinancing, changes in governmental laws, rules and regulations or actions taken by regulatory authorities, economic, regulatory, political and governmental conditions that affect the shipping and the LNG industry, potential liability from pending or future litigation, and potential costs due to environmental damage and vessel collisions, general domestic and international political conditions, potential disruption of shipping routes due to accidents, political events or international hostilities, geopolitical events including ongoing conflicts and hostilities in the Middle East and other regions throughout the world and the global response to such conflicts and hostilities, changes in tariffs, trade barriers, sanctions, and embargos, including recently imposed tariffs by the U.S. and the effects of retaliatory tariffs and countermeasures from affected countries, vessel breakdowns, instances of off-hires, the length and severity of epidemics and pandemics, the impact of public health threats and outbreaks of other highly communicable diseases, the amount of cash available for distribution, and other factors.

Please see the Partnership’s filings with the SEC for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Partnership disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) — Aether Holdings, Inc. (NASDAQ: ATHR) (“we,” “us,” “our,” “Aether,” or the “Company”), an emerging financial technology holding company offering software, data, and artificial intelligence technology to institutional and self-directed investors, is pleased to announce the closing of its initial public offering of 1,800,000 shares of its common stock at a price to the public of $4.30 per share on April 11, 2025.

The gross proceeds to Aether from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $7,740,000, and net proceeds were approximately $6,520,000. The shares sold in the offering began trading on the Nasdaq Capital Market under the symbol “ATHR” on April 10, 2025.

Aether intends to use the net proceeds from the offering to further the design and development of its products, hire additional employees, including in the areas of finance, accounting, sales, marketing, securities research, and copy editing, sales and marketing expenses, and general corporate purposes and working capital.

The Benchmark Company, LLC and Axiom Capital Management, Inc. acted as joint book-running managers for the offering. Ellenoff Grossman & Schole LLP acted as counsel to Aether. Sheppard, Mullin, Richter & Hampton LLP acted as counsel to the underwriters. ZH CPA LLC are Aether’s registered independent auditors.

A registration statement relating to Aether’s initial public offering has been filed with the U.S. Securities and Exchange Commission, and was declared effective on April 9, 2025. Final prospectuses for the offering and related resale by selling stockholders were filed with the U.S. Securities and Exchange Commission on April 11, 2025. This registration statement and final prospectuses can be obtained by visiting the SEC website at www.sec.gov. Please see such registration statement and final prospectuses for additional information regarding Aether.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aether Holdings, Inc.

Aether Holdings, Inc. (NASDAQ:ATHR) is an emerging financial technology holding company focused on transforming the way investors navigate the markets. Leveraging decades of market expertise and cutting-edge technology, Aether delivers proprietary tools, data, and research to empower traders with actionable insights and enhanced decision-making capabilities.

Aether’s flagship platform, SentimenTrader.com, is designed to serve both retail and institutional investors by offering advanced sentiment analysis through the use of machine learning (ML) and artificial intelligence (AI) capabilities. With over 20 years of sentiment data integrated into its systems, Aether aims to provide its users with a powerful combination of technology and expertise, enabling them to make informed decisions to level-up their trading in the markets.

Aether is committed to building an ecosystem that supports smarter, data-driven trading strategies, reinforcing its mission to empower the investing community and redefine excellence in fintech.

Find out more about Aether Holdings at https://helloaether.com/

By integrating advanced technologies, including artificial intelligence tools with the critical thinking and analytical abilities of its team of evidenced-based trading veterans, Aether aims to provide its users with a powerful combination of technology and expertise, enabling them to make informed decisions to level-up their trading in the markets.

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Aether’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements (which includes statements regarding the commencement of trading in our common stock and the closing of the offering described herein) are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control. For Aether, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following which are, and will be, exacerbated by any worsening of global business and economic environment: the impact of governmental laws and regulations, including the regulation of artificial intelligence; our failure to maintain and protect our reputation for trustworthiness and independence; our ability to develop new products or effectively market our products and services; our ability to continue to evolve and adapt our technology, including further adoption of artificial intelligence and machine learning techniques; our ability to attract new users and to persuade existing users to renew their subscriptions with us and to purchase higher subscription tiers from us; our ability to expand the coverage of our products to include foreign markets and additional types of financial instruments; our future capital needs; our ability to expand our revenue streams beyond the subscriber model; difficulties with third-party services we rely on or will rely on; and similar risks and uncertainties associated with the business of a start-up business operating a in a regulated industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Company Contact

Frank Cid
(347)-363-0886
[email protected]

Investor Relations Contact

Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
(347)-947-2093
Email: [email protected]

Media Contact

Jessica Starman, MBA
[email protected]

CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Medicaid Services’ (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies.

“Organogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implementation to review its coverage policies to ensure that patients have access to products with “high quality evidence of effectiveness”, which we believe includes real-world evidence,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board of Organogenesis. “Real-world evidence not only demonstrates a product’s safety and efficacy, but also outcomes in actual clinical use.”

Gillheeney continued, “Although we believe this is an important first step for the industry, we believe coverage policies alone are not sufficient to address rapidly escalating Medicare costs while ensuring cost-effective patient care and innovation. To that end, we recommend CMS implement an integrated coverage and payment policy. As a leader in the space, we will continue to bring stakeholders together to develop and advocate for such an integrated policy that will ensure patient access to the most appropriate products while achieving significant savings to Medicare.”

Organogenesis has been a leader in regenerative medicine for four decades, innovating and manufacturing a diverse portfolio of highly effective advanced wound care therapies. The Company is a pioneer in bioengineered living cell products, creating the skin substitutes and CTP category in the chronic wound space. Organogenesis has multiple technology platforms supporting clinically proven safe and effective solutions that substantially improve outcomes while lowering the overall cost of care.

About Organogenesis Holdings Inc. 

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

HONG KONG and RENO, Nev., April 11, 2025 (GLOBE NEWSWIRE) — Tianci International, Inc. (the “Company” or “Tianci”), a global logistics service provider specializing in ocean freight forwarding, today announced the closing of its public offering (the “Offering”) of an aggregate of 1,750,000 shares of common stock at a public offering price of US$4.00 per share, for total gross proceeds of $7,000,000, before deducting underwriting discounts, commissions, and other related expenses.

The Company has granted American Trust Investment Services, Inc., the representative of the underwriters, a 45-day option to purchase up to an additional 262,500 shares at the public offering price, less underwriting discounts to cover over-allotments, if any. The total proceeds from the Offering are expected to be approximately US$8,050,000 if the representative of the underwriters exercises its option to purchase additional shares in full. Shares of the Company’s stock began trading on the Nasdaq Capital Market under the symbol “CIIT” on April 10, 2025.

The Offering was conducted on a firm commitment basis. The Company intends to use the proceeds from the Offering for logistics promotion and marketing, working capital and general corporate purposes, and recruitment of talented personnel.

American Trust Investment Services, Inc. acted as representative of the underwriters for the Offering. Kaufman & Canoles, P.C. acted as U.S. securities counsel to the Company. Han Kun Law Offices LLP and Parsons Behle & Latimer acted as Hong Kong legal advisers and Nevada legal counsel respectively, to the Company. Ye & Associates, P.C. acted as U.S. counsel to American Trust Investment Services, Inc. in connection with this Offering.

A registration statement on S-1 (File No. 333-280089) was filed with the Securities and Exchange Commission (“SEC”) and was declared effective by the SEC on April 09, 2025. A final prospectus relating to the Offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to this Offering, when available, may be obtained from American Trust Investment Services, Inc., 230 W Monroe St # 300, Chicago, IL 60606, Telephone: +1 (312) 382-7000; Email: [email protected]

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Tianci International, Inc.

Tianci International Inc., through its subsidiary Roshing, provides global logistics services specializing in ocean freight forwarding, including container and bulk goods shipping. Operating under an asset-light model, Roshing’s logistics solutions are tailored to meet the diverse needs of its customers across the Asia-Pacific, including Japan, South Korea, and Vietnam. Beyond logistics, the company generates revenue from the sale of electronic parts and business consulting services. The company’s mission is to provide customers with efficient, reliable, and safe shipping services that create value.

For more information, please visit the Company’s website: tianci-ciit.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Tianci International, Inc.
Investor Relations
Email: [email protected]

EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
[email protected]

Investors:

Julian Pei
Head of Investor Relations and Corporate Finance
[email protected]